



Promise.

A passion for improving the health of patients worldwide.
A drive to expand our potential through innovation.
A commitment to position our company for long-term success.
This is the essence of Abbott:
A Promise for Life.

Founded in 1888 by Dr. Wallace C. Abbott, a Chicago physician, Abbott is a global, diversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals, nutritional products for children and adults, and medical products, including devices, diagnostic tests and instruments. Headquartered in north suburban Chicago, Abbott employs nearly 90,000 people and markets its products worldwide.

Abbott is focused on advancing patient care by developing innovative solutions in pharmaceuticals, diagnostics, medical devices and nutritional products.

2	Financial Highlights	18	Diagnostics – Immunoassay and Clinical Chemistry
4	Pharmaceuticals	19	Diagnostics Hematology
8	Nutritional Products	19	Diagnostics Molecular
12	Medical Devices	19	Diagnostics Point of Care
14	Medical Devices Diabetes Care	20	History
14	Medical Devices Cardiovascular Devices	23	Rankings
15	Medical Devices Vision Care	24	Global Citizenship
15	Medical Devices Animal Health	26	Five-Year Financial Summary
16	Diagnostics	28	Plant Locations
18	Diagnostics Core Laboratory	28	Directors
		29	Senior Management and Corporate Vice Presidents



Valentina Mareno – Optium Xceed – Cordoba, Argentina: Diagnosed with Type 1 diabetes, Valentina uses Abbott's *Optium Xceed* blood glucose monitor. Unlike many monitors that only measure blood glucose levels, the *Optium Xceed* meter is capable of measuring both blood glucose and blood ketone levels.

Financial Highlights

In 2010, Abbott reported sales of \$35.2 billion, growth of 14.3 percent. Abbott's businesses fall into three categories: Durable Growth, Innovation-Driven Device and Proprietary Pharmaceuticals.

Durable Growth businesses, which include Established Pharmaceuticals, Nutritionals, Core Diagnostics and Diabetes Care, account for 40 percent of total sales. **Innovation-Driven Device** businesses, which consist of Vascular, Molecular Diagnostics and Vision Care, make up 20 percent of total sales. And, **Proprietary Pharmaceuticals**, including Abbott's U.S. and international proprietary pharmaceutical products, account for 40 percent of total sales.

In addition, 2010 marked the 38th straight year Abbott's dividend has increased. Abbott has paid 348 consecutive quarterly dividends since 1924.


Net Sales Worldwide

(dollars in billions)



5-Year Total Return

(as of December 31, 2010)



Consistent Dividends

(dollars per share declared)



Pharmaceuticals

Abbott medicines treat some of the world's most serious and prevalent diseases, including rheumatoid arthritis, Crohn's disease, lipid disorders, kidney disease, prostate cancer, thyroid disease and HIV.

Amanda Graciola (Florianópolis, Brazil): Amanda Graciola is like any teenage girl — she enjoys shopping and listening to pop music. She takes *Creon* for her exocrine pancreatic insufficiency, a condition often associated with cystic fibrosis.



Immunology



Metabolics



Virology



Cardiovascular



Pharmaceuticals

Abbott is dedicated to discovering, developing and marketing important treatment options that improve patient health. Abbott sells pharmaceutical products in several therapeutic areas.

Anesthesia. Provides inhalation anesthetic agents, neuromuscular blockers, sedatives and other analgesic pain therapies.

Ultane, Sevorane (sevoflurane) Inhalation anesthetic for both inpatient and outpatient procedures, for adult and pediatric use.

Anti-Infectives. Antibiotics for the treatment of respiratory infections and skin infections.

Biaxin, Klaricid, Klaricid (clarithromycin), Biaxin XL, Klaricid OD (clarithromycin extended-release formulation) Oral macrolide antibiotic for the treatment of upper and lower respiratory tract infections. Clarithromycin is also used for skin and skin-structure infections, treatment and prevention of Mycobacterium avium complex (MAC) and eradication of the ulcer-causing bacterium H. pylori.

Cardiovascular. Includes anti-hypertensive medicines for reducing high blood pressure, treating congestive heart failure and medicines for managing cholesterol and triglyceride abnormalities.

Blopress, Tiadyl (candesartan) Angiotensin-2 antagonist for hypertension. (Marketed outside the United States.)

Niaspan (niacin extended-release tablets), Simcor (niacin extended-release/simvastatin), TriCor (fenofibrate tablets), Trilipix (fenofibric acid) delayed release Used along with diet and exercise to address lipid abnormalities.

Omacor (omega-3-acid ethyl esters 90) Gelatin capsules of pharmaceutical-grade omega-3 fatty acid for adjuvant treatment following a heart attack. It is used in addition to other standard therapies. (Marketed outside the United States.)

Simdax (levosimendan) Injectable for acute congestive heart failure. (Marketed in Latin America only.)

Gastroenterology. Medications used to treat disorders and conditions associated with the gastrointestinal tract.

Duphalac (lactulose) Prebiotic that stimulates the growth and activity of beneficial bacteria of the intestinal flora.

Hormonal Health. Oral and topical hormonal treatments.

AndroGel (testosterone gel) Testosterone gel to treat men with a deficiency or absence of testosterone.

Immunology. Medication used to treat some diseases of the immune system.

Humira (adalimumab) Self-injectable, TNF-blocking, recombinant monoclonal antibody for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, moderate to severe Crohn's disease, moderate to severe chronic plaque psoriasis and moderate to severe polyarticular juvenile idiopathic arthritis.

Metabolics. Includes medicines for the treatment of thyroid disease.

Synthroid (levothyroxine sodium) Synthetic thyroid hormone for the treatment of hypothyroidism and subclinical hypothyroidism.

Neuroscience and Pain Care. Medications to treat neurological conditions.

Depakote ER (divalproex sodium, extended-release tablets), Depakote, Epival, Valcote (divalproex sodium enteric-coated tablets) Anti-epileptic agent (adult/pediatric) also used for the treatment of the manic episodes of bipolar disorder (adult) and for the prevention of migraine headaches (adult).

Duodopa (levodopa/carbidopa) Treatment system for advanced Parkinson's disease (Marketed outside the United States.)

Serc (betahistine dihydrochloride) Used for the treatment of Ménière's disease and vestibular vertigo.

Pancreatic Enzymes. Used for the treatment of exocrine pancreatic insufficiency.

Creon (pancrelipase) Pancreatic enzyme used for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.

Pediatric and Neonatal. Medications for newborns and pediatric patients with serious respiratory conditions.

Survantia (beractant) Lung surfactant used to treat and prevent respiratory distress syndrome (RDS) in premature newborns.

Synagis (palivizumab) Monoclonal antibody for the prevention of serious lower-tract respiratory infection due to respiratory syncytial virus (RSV) infection in pediatric patients at high risk of RSV. (Marketed outside the United States.)

Renal Care. Includes oral and injectable activated vitamin D agents developed to treat patients with complications of chronic kidney disease.

Zemplar (paricalcitol injection and capsules) Therapy for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease.

Urology and Reproductive Health. Includes medicines for the palliative treatment of advanced prostate cancer, endometriosis, anemia associated with uterine fibroids and central precocious puberty.

Lupron Depot, Lucrin (leuprolide acetate depot suspension) Synthetic hormone for the treatment of advanced prostate cancer, endometriosis, preoperative treatment of anemia associated with uterine fibroid tumors in combination with iron, and central precocious puberty.

Vaccines. Used to protect against the influenza virus.

Influvac Influenza vaccine.

Virology. Medications to treat HIV.

Kaletra/Aluvia (lopinavir/ritonavir) Protease inhibitor used in conjunction with other antiretroviral agents for the treatment of HIV.

Norvir (ritonavir) Protease inhibitor used in conjunction with other antiretroviral agents for the treatment of HIV.

Nutritional Products

Abbott offers some of the world's most trusted brands in pediatric nutrition, therapeutic nutrition and performance nutrition, including specially formulated medical nutrition products.

Sergey Knyazitenkov (Moscow, Russia): Sergey Knyazitenkov suffered a broken leg while playing hockey. After his surgery, Sergey received *Ensure*, which provided quality protein and essential vitamins and minerals, to aid in his recovery.



Pediatric Nutrition



Therapeutic Nutrition



Performance Nutrition



Nutritional Products

Abbott is a leader in providing trusted pediatric and adult nutrition formulas, shakes, bars, snacks and tube-feeding products to improve people's quality of life.

Pediatric Nutrition. Abbott develops products that support the growth and development of infants and children, and makes these products available in innovative, consumer-friendly packaging. Specialty formulations include products for premature and low-birth-weight infants and products for infants and children with special tolerance or nutritional needs.

<i>Gain Advance</i>	A nutritional supplement for children 6 months to 1 year old during the transition to solid foods. <i>Gain Advance</i> contains the Eye-Q system of nutrients, nucleotides and increased levels of protein and energy to support brain development, the immune system and overall growth. (Marketed outside the United States.)
<i>Gain Plus Advance</i>	Nutritional choice for children 1 to 3 years old. The Eye-Q system is also available with <i>Gain Plus Advance</i> , and it contains pre- and probiotics (synbiotics) to help support children's natural defenses. (Marketed outside the United States.)
<i>Gain Kid, Gain School</i>	Growth-focused nutritional supplements for children 3 years old and beyond, delivering more than 30 essential nutrients. <i>Gain Kid</i> is also available with the Eye-Q system of nutrients. (Marketed outside the United States.)
<i>Pedialyte</i>	Oral electrolyte maintenance solution to help replace vital minerals and nutrients lost during diarrhea and vomiting to help prevent dehydration. Also available as <i>Pedialyte Powder Packs</i> , <i>Pedialyte Freezer Pops</i> and <i>Pedialyte Singles</i> .
<i>PediaSure, PediaSure SideKicks and PediaSure Complete</i>	Portfolio of pediatric nutritional products in a variety of flavors and designed for children 1 to 13 years old. <i>PediaSure</i> is a source of complete, balanced nutrition for kids falling behind on growth. <i>PediaSure SideKicks</i> is an oral source of supplemental nutrition for picky eaters who are growing fine. In addition, there are a variety of <i>PediaSure</i> products that are specifically designed for tube-feeding purposes. <i>PediaSure Complete</i> (marketed outside the United States) contains synbiotics.
<i>Similac</i>	A full line of milk- and soy-based infant and toddler formulas that support healthy immune system, brain, eye, and bone development. The line also includes highly specialized products to meet the unique needs of premature and low-birth-weight babies, including <i>Similac Human Milk Fortifier</i> , <i>Similac Special Care</i> and <i>Similac Expert Care NeoSure</i> .
<i>Similac Advance</i>	Milk-based infant formula that provides complete nutrition for baby's first year. It has <i>EarlyShield</i> – specially designed to support an infant's developing immune system, brain and eyes, and strong bones. Also includes a blend of immune-supporting nucleotides, and prebiotics and carotenoids. It is the only leading formula with no palm olein oil, and has been clinically shown to support greater calcium absorption for strong bones.
<i>Similac Advance Organic</i>	Organic infant formula that is certified USDA Organic with the trusted nutritional benefits of <i>Similac</i> infant formula and the wholesomeness of organic milk.
<i>Similac Expert Care Alimentum</i>	A formula for infants with colic symptoms due to protein sensitivity. A supplemental beverage for children with severe food allergies, sensitivity to intact protein, protein maldigestion or fat malabsorption.
<i>Similac Expert Care NeoSure</i>	A special nutrient-enriched formula for babies born prematurely. It is designed to meet the unique nutritional needs of premature infants to support development and excellent catch-up growth through the first full year of life.
<i>Similac Go & Grow</i>	Milk-based and soy-based, iron-fortified formulas for older babies and toddlers, 9 to 24 months old. Specially formulated to help bridge the nutritional gaps that can be associated with the transition to table foods.

<i>Similac Sensitive</i>	A milk-based infant formula that offers a unique blend of carbohydrates and reduced levels of lactose to help ease fussiness and gas due to lactose sensitivity. <i>Similac Sensitive</i> has <i>EarlyShield</i> to support baby's developing immune system, brain and eyes, and strong bones.
<i>Similac Soy Isomil</i>	Soy infant formula for common feeding problems such as fussiness and gas. <i>Similac Soy Isomil</i> has <i>EarlyShield</i> to support baby's developing immune system, brain and eyes, and strong bones.
<i>Similac Sensitive For Spit Up</i>	Milk-based formula with added rice starch to help reduce frequent spit-up.

Performance Nutrition. Abbott offers a broad selection of nutrition bars, shakes and related products that satisfy a wide range of consumer nutrition needs.

<i>EAS</i>	A leading brand of specialized sports nutrition bars, shakes and dietary supplements designed to help athletes and fitness enthusiasts meet their fitness, performance and endurance goals.
<i>ZonePerfect</i>	A leading brand of nutrition bars that provide convenient, all-natural nutrition for busy people.

Therapeutic Nutrition. Abbott offers medical nutritional products and devices for patients with special dietary needs who require tube feeding or other nutritional interventions due to complex illness or injury. Abbott also offers specialized nutrition products for infants and children with multiple food allergies, severe gastrointestinal impairment or metabolic diseases.

<i>Companion, EnteraLite Infinity, Patrol, Flexiflo Quantum</i>	Complete line of enteral feeding pumps, tubes and devices.
<i>EleCare</i>	Amino acid-based formula for infants and children with severe food allergies or gastrointestinal disorders.
<i>Ensure</i>	The family of <i>Ensure</i> nutrition shakes includes <i>Ensure</i> , <i>Ensure Plus</i> , <i>Ensure Muscle Health</i> , <i>Ensure Immune Health</i> , <i>Ensure Bone Health</i> and <i>Ensure Clinical Strength</i> . The shakes satisfy a variety of nutritional needs and provide 24 essential vitamins and minerals. <i>Ensure Muscle Health</i> and <i>Ensure Clinical Strength</i> shakes have <i>Revigor</i> , a source of HMB (beta-hydroxy-beta-methylbutyrate, an amino-acid metabolite) and protein to help rebuild muscle and strength naturally lost over time.
<i>Glucerna, Glucerna Triple Care</i>	A therapeutic nutritional product for people with diabetes or patients with impaired glucose tolerance. Available in shakes, meal bars, cereal, snack bars and tube-feeding formulations. <i>Glucerna Triple Care</i> (marketed outside the United States) is an advanced <i>Glucerna</i> formulation to improve glycemic control and help people with diabetes achieve or maintain optimal weight management.
<i>Jevity</i>	Fiber-containing liquid formula line available with various protein and caloric levels for both short- and long-term tube feeding.
<i>Juven, Abound</i>	Therapeutic nutrition drink mix to help patients build lean body mass to support wound healing.
<i>Nepro and Suplena with Carb Steady</i>	Specialized nutritional products for people with chronic kidney disease.
<i>Oxepa, Pulmocare</i>	Specialized nutritional products for patients with respiratory conditions. <i>Oxepa</i> provides therapeutic nutrition for modulating inflammation in sepsis, acute lung injury, and acute respiratory distress syndrome. <i>Pulmocare</i> provides nutrition support for patients with chronic obstructive pulmonary disease (COPD).
<i>Vital Jr.</i>	Designed for children ages 1 to 13 with malabsorption, maldigestion, or impaired GI function. It is scientifically formulated to help kids absorb the nutrients they need to grow and develop.

Medical Devices

Abbott drives innovation in the fast-paced medical devices market. Our technology is advancing vision care, diabetes management and the treatment of vascular disease.

Akira Kitamoto (Tokyo, Japan): After suffering two heart attacks, Akira Kitamoto's doctor treated him with *Xience V*, Abbott's market-leading drug-eluting stent. Prior to the procedure, he often experienced shortness of breath and chest discomfort, but now he has resumed playing golf and traveling.



Vision Care



Diabetes Care

Cardiovascular Devices



Medical Devices

Diabetes Care. Abbott Diabetes Care is committed to improving the lives of people with diabetes by providing innovative glucose monitoring systems that offer patients and health care professionals fast, convenient and accurate results.

FreeStyle Freedom Lite Blood Glucose Monitoring System	Easy-to-hold, easy-to-read blood glucose monitoring system that uses a 0.3 microliter blood sample, has approved alternate sites for testing, features a 5-second average test time and requires no coding.
FreeStyle Lite Blood Glucose Monitoring System	Small, discreet blood glucose monitoring system that offers key features such as no coding and small blood sample size (0.3 microliter).
Precision Xceed Pro Blood Glucose and Beta Ketone Monitoring System	A hand-held, point-of-care blood glucose monitoring system used in the hospital.
Precision Xtra Blood Glucose and Beta Ketone Monitoring System	A meter capable of measuring both blood glucose and blood ketone levels.

Cardiovascular Devices. Abbott Vascular markets a broad portfolio of coronary, endovascular, vessel closure and structural heart technologies used in the treatment of cardiac and vascular care.

Coronary

ABSORB	The world's first drug-eluting bioresorbable vascular scaffold for the treatment of coronary artery disease. The device restores blood flow to a clogged vessel, provides support to the vessel and then dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. (Approved in CE Mark countries only. Currently in development and not available for sale in the United States.)
HI-TORQUE guide wires (for coronary and peripheral)	Full array of guide wires designed to assist clinicians in accessing lesions, navigating tortuous anatomy, and supporting the delivery of bulky devices.
MULTI-LINK VISION, MULTI-LINK MINI VISION stents	Thin-strut metallic coronary stents based on cobalt chromium technology. <i>MULTI-LINK VISION</i> is for use in vessels 2.75 mm to 4.0 mm and <i>MULTI-LINK MINI VISION</i> is for use in small vessels (2.0 mm to 2.5 mm).
MULTI-LINK 8	A next-generation, cobalt chromium, bare-metal stent with an excellent delivery system designed for superb flexibility and deliverability. <i>MULTI-LINK 8</i> is available in longer lengths up to 38 mm.
TREK and MINI-TREK	Coronary dilatation catheters used in angioplasty procedures and designed to open narrowed coronary arteries. <i>MINI-TREK</i> comes in 1.5 mm to 2.0 mm sizes only.
XIENCE V	Drug-eluting coronary stent system that combines a cobalt chromium stent with the drug everolimus to treat coronary lesions in patients with coronary artery disease.
XIENCE Nano	A 2.25 mm drug-eluting stent that is designed to treat small vessels. (Currently an investigational device in the United States.)
XIENCE PRIME, XIENCE PRIME (for critical limb ischemia)	A next-generation, drug-eluting stent with a novel stent design and modified delivery system that allows greater flexibility and enhanced deliverability. (Approved in CE Mark countries only. Currently an investigational device in the United States.)

Endovascular

Acculink, Accunet, Xact, Emboshield NAV	Self-expanding nitinol stents designed for use in the carotid arteries of the neck. <i>Accunet</i> and <i>Emboshield NAV</i> are embolic protection systems used to capture plaque fragments (emboli).
Armada 14 PTA Catheter, Fox Balloons (FoxCross, Fox Plus, Fox sv)	Peripheral dilatation catheters used in angioplasty procedures and designed to open narrowed arteries.

Structural Heart

MitraClip	A less-invasive, new and safe treatment option that provides meaningful and sustained clinical benefits for select patients suffering from serious mitral regurgitation. (Approved in CE Mark countries only. Currently an investigational device in the United States.)
---------------------------	--

Vessel Closure

Perclose ProGlide, Perclose AT, ProStar XL	Suture-mediated vessel closure devices designed to expedite recovery following diagnostic or interventional catheterization procedures.
StarClose SE	Extravascular vessel closure device designed to expedite recovery following diagnostic or interventional catheterization procedures.

Vision Care. Abbott's vision care business offers a range of technologies to treat vision disorders, such as cataracts, near-sightedness, far-sightedness and symptoms of chronic dry eye.

Cataract Products

Synchrony Accommodating IOL	A next-generation implant designed to mimic the eye's natural ability to change focus and deliver improved vision at all distances following cataract surgery. (Currently under FDA review in the United States.)
Tecnis Monofocal and Multifocal IOLs	Implants used in cataract surgery to replace the natural lens with one that improves vision at a single focal point (monofocal) or provides near, intermediate and distance vision with reduced dependence on glasses or contact lenses (multifocal).
Tecnis Toric IOL	Implant used in cataract surgery to replace the eye's natural lens with one that corrects preexisting corneal astigmatism, delivering significantly improved distance vision without the need for glasses or contact lenses. (Not yet approved in the United States.)

Corneal Products

Blink Tears Lubricating Eye Drops	Mimics the natural elements of tear film and provides other benefits that alleviate the symptoms of dry eyes.
RevitaLens Ocutec	Next-generation multi-purpose disinfecting solution for silicone hydrogel and conventional soft contact lenses.

Refractive Products

iFS Advanced Femtosecond Laser	Ultrafast laser that focuses pulses of light below the surface of the cornea to create the corneal flap before a LASIK treatment is performed.
STAR S4 IR Excimer Laser System	Computer-driven ultraviolet laser that corrects refractive errors by reshaping the cornea during LASIK procedures.
WaveScan WaveFront System	Measures imperfections and produces a detailed map of the eye, which is digitally transferred to the excimer laser, providing high levels of precision and accuracy.

Animal Health. Abbott Animal Health is a leader in specialty and surgical products for the veterinary market.

AlphaTRAK blood glucose monitoring system	Blood glucose monitoring system calibrated and validated for dogs, cats, horses, ferrets, mice and rats that provides accurate results within seconds.
Fluid Therapy	Complete line of IV fluids, sets, catheters and accessories that provide venous access, keep organs properly perfused and help maintain blood pressure.
PropoFlo (propofol)	Anesthetic injection agent approved for use in dogs for induction and maintenance of general anesthesia.
SevoFlo (sevoflurane)	Inhalant anesthetic that provides veterinarians rapid induction of anesthesia and excellent control during the maintenance phase of anesthesia.

Diagnostics

Abbott is a global leader in diagnostics. Health care professionals use our diagnostic systems and tests to protect the blood supply, monitor medication levels and assist in the diagnosis and treatment of disease.

Dr. Martin Kroll (Boston, Mass.): Dr. Martin Kroll is committed to fighting HIV. He uses Abbott's *Architect* HIV Ag/Ab Combo assay, which can simultaneously detect HIV antigen and antibodies, allowing for earlier diagnosis of infection. Earlier diagnosis helps him care for his patients faster.



*Martin Kroll, M.D.
Chief
Laboratory Medicine*

Molecular



Point of Care



Core Laboratory



Diagnostics

Core Laboratory Diagnostics. Abbott Core Laboratory Diagnostics offers a broad range of innovative instruments and tests across key segments in the global diagnostics market, including hospitals, reference laboratories, blood banks, physician offices and clinics.

Immunoassay and Clinical Chemistry. Includes systems and assays to measure a variety of antigens, antibodies and analytes found in the blood and to diagnose and monitor diseases and therapies. Also includes blood-screening instrumentation and assays used to ensure the safety of the blood supply.

<i>AbbottLink</i>	Software that transmits instrument performance information to Abbott's service operations through the Internet, enhancing the remote identification and rapid resolution of technical issues on select analyzers.
<i>ABBOTT PRISM</i>	Fully automated analyzer designed for batch/continuous access and STAT processing for blood and plasma centers and blood banks to screen donated blood and plasma for multiple viral assays. Menu includes Hepatitis (HBsAg, HCV, Anti-HBc), Retrovirus (HIV and HTLV) and Chagas. (All assays available in the United States except for HIV combo.)
<i>ACCELERATOR Automated Processing Systems</i>	Automates the labor-intensive sample identification, routing, centrifugation and storage logistics in the laboratory. <i>ACCELERATOR APS</i> improves process consistency, reduces dependency on manual labor and enhances overall operator safety.
<i>ARCHITECT ci4100</i>	Clinical chemistry analyzer that performs diagnostic tests to monitor general health including a patient's levels of sodium, potassium, chloride and organ function. The <i>ci4100</i> is an automated analyzer that integrates both immunoassay and chemistry testing on one platform.
<i>ARCHITECT c4000, c8000, c16000</i>	Low-, medium- and high-volume clinical chemistry analyzers with broad testing menus to facilitate routine and specialty chemistry testing.
<i>ARCHITECT ci8200, ci16200</i>	Analyzers that integrate the <i>ARCHITECT c8000</i> and <i>c16000</i> clinical chemistry analyzers with the <i>i2000SR</i> instrument to provide a consolidated workstation to perform both clinical chemistry and immunoassay testing.
<i>ARCHITECT i4000sr, i2000sr, i1000sr</i>	Modular analyzers that provide immunoassay testing. Menu includes tests for cancer, infectious disease, cardiovascular and thyroid disease, fertility and pregnancy.
<i>AxSYM Plus</i>	Automated immunoassay analyzer with continuous access and STAT capabilities. Menu includes tests for cancer, cardiovascular and thyroid disease, drugs of abuse, fertility, hepatitis, pregnancy and infectious disease.
<i>IMx</i>	Automated benchtop analyzer for immunoassay testing. Menu includes tests for cardiovascular and thyroid disease, cancer and fertility.
<i>Instrument Manager</i>	Software that provides connectivity and functionality across the entire laboratory, reducing turnaround time and labor dependency, while improving the quality of results.
<i>TDx, TDx Fix</i>	Automated benchtop analyzers for monitoring therapeutic drug levels. Menu includes theophylline, vancomycin, drugs of abuse and thyroid tests.

Hematology. Abbott develops, manufactures and markets *CELL-DYN* hematology systems used to perform sophisticated blood cell analysis.

<i>CELL-DYN Ruby, 3700, 3200</i>	Complete line of highly automated hematology analyzers to meet the testing needs of mid-volume laboratories or CLIA moderate laboratories.
<i>CELL-DYN Emerald, 1800</i>	Low-volume, automated hematology analyzer for small to midsize clinical laboratories.
<i>CELL-DYN Sapphire</i>	High-volume, automated hematology analyzer that incorporates monoclonal antibody tests, reducing the need for external sample analysis.

Molecular Diagnostics. Abbott Molecular offers innovative tests and instruments for early detection of pathogens and genomic and chromosomal changes, allowing for earlier diagnosis, selection of appropriate therapies and disease monitoring.

<i>Abbott m2000 and Abbott RealTime tests for HIV-1, HBV, HCV, HCV Genotyping, HPV, CT/NG, CT mS9 and KIF6.</i>	Automated system integrates sample preparation and extraction with real-time polymerase chain reaction (PCR) amplification and detection technology. Menu includes tests for human immunodeficiency virus (HIV-1), hepatitis B virus (HBV), hepatitis C virus (HCV), HCV genotyping, human papillomavirus (HPV), Chlamydia trachomatis (CT) / Neisseria gonorrhoeae (NG), CT, methylated septin 9 for colorectal cancer (<i>mS9</i>), and KIF6, a genetic marker used in the assessment of coronary heart disease risk and statin treatment. (Not all tests are available in the United States.)
<i>Cystic Fibrosis Genotyping Assay</i>	Qualitative in vitro diagnostic device used to genotype a panel of mutations and variants in the cystic fibrosis transmembrane conductance regulator gene in genomic DNA isolated from human whole-blood specimens.
<i>Fluorescence in-situ Hybridization (FISH) Probe Technology</i>	Genomic DNA tests for chromosomal changes associated with congenital disorders and cancer.
<i>FlexID</i>	A bioidentification system that provides the identification, genotyping, and characterization of known and emerging microorganisms. Current assays for application in bioresearch, forensics, food testing and quality control. (Not for use in diagnostic procedures.)
<i>PathVysion HER-2 DNA Probe Kit</i>	Detects the HER-2/neu gene in breast cancer patients. Patients who have extra copies of this gene are candidates for treatment with Herceptin, a targeted monoclonal antibody treatment.
<i>UroVysion Bladder Cancer Kit</i>	DNA-based test for the initial diagnosis of patients suspected of having bladder cancer presenting with hematuria, and the monitoring of cancer recurrence in patients diagnosed with bladder cancer.
<i>ViroSeq HIV-1</i>	Genotyping system used as an aid in monitoring and treating HIV infection. Detects HIV-1 mutations associated with drug resistance.

Point of Care. Abbott Point of Care develops, manufactures and markets critical medical diagnostic and data management products for rapid blood analysis.

<i>i-STAT System</i>	An advanced, handheld diagnostic tool that provides real-time, lab-quality results within minutes to accelerate patient-care decision making. The <i>i-STAT</i> System has the industry's most comprehensive menu of tests in a single platform, including tests for blood gases, electrolytes, chemistries, coagulation, hematology, glucose, and cardiac markers.
----------------------	---

A tradition of innovation.

For more than 120 years, Abbott has been a pioneer in developing innovative solutions that improve health and the practice of health care. In 1888, 30-year-old Wallace C. Abbott, M.D., began making a new form of medicine. Using the active – or alkaloid – part of a medicinal plant, he formed tiny pills, called “dosimetric granules,” which provided a measured amount of the drug. The demand for these accurate granules soon far exceeded the needs of his own practice. From a small operation based above Dr. Abbott’s pharmacy, Abbott Laboratories has evolved into one of the world’s leading health care companies.

1888	Dr. Abbott begins producing dosimetric granules in his apartment on Chicago’s North Side.
1900	The business is officially incorporated in Illinois as the Abbott Alkaloidal Company.
1915	The company changes its name to Abbott Laboratories.
1920	Dr. Abbott breaks ground for a new manufacturing facility in North Chicago, Ill.
1929	Abbott stock is listed on the Chicago Stock Exchange. The offering is 20,000 shares for \$32 each.
1931	Abbott establishes its first international affiliate in Montreal, Canada. The company’s international presence will grow steadily.
1936	Abbott introduces the anesthetic agent Pentothal, developed by Abbott scientists Drs. Ernest Volwiler and Donalee Tabern. For this discovery, they are named to the U.S. Inventors Hall of Fame in 1986.
1941	Abbott is one of the five pioneers in the United States to start commercial production of penicillin.
1952	Erythrocin, a new antibiotic with good activity against grampositive bacteria, is introduced.
1962	Abbott enters a joint venture with Dainippon Pharmaceutical Co., Ltd., of Osaka, Japan, to manufacture radiopharmaceuticals. Major plant expansions are completed in England, Italy and France.
1964	The company acquires M&R Dietetic Laboratories of Columbus, Ohio, which eventually becomes Abbott’s Ross Products Division.
1965	Abbott moves major operations to Abbott Park, a 420-acre site southwest of its North Chicago headquarters.
1973	Abbott forms its diagnostics division to bring together all diagnostic products and services. The company also introduces <i>Ensure</i> , the first adult medical nutritional.

1977	TAP Pharmaceuticals is formed as a joint venture between Abbott and Takeda Chemical Industries Ltd., of Japan.
1983	<i>Depakote</i> , a new treatment for epilepsy, is approved in the United States.
1985	Abbott wins U.S. approval to market the world’s first diagnostic test for HIV/AIDS. TAP receives approval for <i>Lupron</i> , a new therapy for prostate cancer.
1987	<i>Hytrin</i> , a new cardiovascular drug for the treatment of hypertension, receives Food and Drug Administration (FDA) approval.
1988	Abbott celebrates its centennial. The <i>IMx</i> immunoassay system is introduced and goes on to become one of the best-selling new products in Abbott’s history.
1990	<i>Biaxin</i> , an important new macrolide antibiotic, is introduced.
1991	Several major products are launched worldwide, including <i>Survanta</i> , for the treatment of neonatal respiratory distress syndrome. Abbott enters the hematology testing market with the acquisition of Sequoia-Turner Corp.
1993	<i>Hytrin</i> receives FDA clearance for use in treating symptoms of benign prostatic hyperplasia, a condition of the prostate. Abbott launches <i>AxSYM</i> , a new, labor-saving diagnostic system.
1994	Abbott introduces sevoflurane, the first truly universal anesthetic, and completes an agreement to cross-license LCR and PCR, two gene amplification technologies.
1995	TAP receives approval for <i>Prevacid</i> , a proton pump inhibitor used in treating ulcers. <i>ABBOTT PRISM</i> , the first fully automated, high-volume blood analyzer, is introduced outside the United States.
1996	The company receives FDA approval for <i>Norvir</i> , a protease inhibitor for the treatment of HIV and AIDS. The company enters the glucose testing market with its acquisition of MediSense Inc.
1997	Abbott acquires the parenteral products business of Sanofi Pharmaceuticals, Inc., and also launches several new products, including an improved version of <i>Similac</i> infant formula in the United States.
1998	Abbott launches <i>Glucerna</i> shakes and snack bars, specially formulated nutritional products for people with diabetes. <i>Depakote</i> surpasses lithium as the most-prescribed drug for treating mania. Abbott launches several pharmaceutical products, including <i>Zemlar</i> , <i>TriCor</i> and <i>Synagis</i> .
1999	Abbott launches <i>ARCHITECT</i> , a next-generation diagnostic system, and acquires Perclose Inc., a leading vascular closure devices company, marking Abbott’s entry into the vascular care business.
2000	Abbott receives FDA approval for several new drugs or new formulations, including <i>Kaletra</i> (an advanced-generation protease inhibitor for the treatment of HIV/AIDS), <i>Biaxin XL</i> (a once-daily version of its flagship antibiotic) and <i>Depakote ER</i> (for migraine prevention).

- 2001** Abbott completes the acquisition of the pharmaceutical business of BASF, including the global operations of Knoll Pharmaceuticals. In addition, Abbott acquires Vysis Inc., a leading genomic disease management company.
- 2002** Abbott receives FDA approval for *Humira* (for moderate to severe rheumatoid arthritis) and *Synthroid* (for hypothyroidism). The company launches *Similac Advance*, *Isomil Advance* and *NeoSure Advance* infant formulas in the United States. Abbott acquires the cardiovascular stent business of Biocompatibles International plc.
- 2003** Abbott launches three new immunodiagnostics systems on the *ARCHITECT* platform. Abbott receives European regulatory approval for *Humira* to treat rheumatoid arthritis. Abbott acquires JOMED's coronary and peripheral intervention business lines, *ZonePerfect* Nutritional Co. and Integrated Vascular Systems Inc.
- 2004** Abbott acquires TheraSense Inc., a leading blood glucose monitoring business, as well as i-STAT Corp. and EAS Inc. Abbott creates Hospira, an independent, publicly traded company. Hospira is one of the largest global specialty pharmaceutical and medication delivery companies serving the hospital market.
- 2005** Abbott introduces several medical devices, including the *Xact/ Emboshield* carotid stent system, *StarClose* vascular closure device and, in the United States, diagnostic devices *ABBOTT PRISM* and *CELL-DYN Sapphire*. Abbott also receives FDA approval for two new indications for *Humira* (psoriatic arthritis and early rheumatoid arthritis).
- 2006** Abbott acquires the vascular business of Guidant Inc., a leader in coronary and vascular products, and Kos Pharmaceuticals, a specialty pharmaceutical company with a significant cholesterol management portfolio. Abbott also launches its *XIENCE V* drug-eluting stent outside the United States.
- 2007** Abbott submits a record number of major products for regulatory approval and launches *Humira* for moderate to severe Crohn's disease and *Niaspan* to treat cholesterol and triglycerides.
- 2008** Abbott receives nine major regulatory approvals, including three indications for *Humira*, *Simcor*, *ARCHITECT i1000sr*, *FreeStyle Navigator* continuous glucose monitoring system, *FreeStyle Freedom Lite*, *XIENCE V* and *Trilipix*. Abbott also concludes its TAP joint venture.
- 2009** Abbott acquires Advanced Medical Optics (AMO), Evolve, Visiogen and Ibis Biosciences. Also, Abbott receives approval for *XIENCE V* in China and Canada, and CE Mark for *XIENCE PRIME*.
- 2010** Abbott receives approval for *XIENCE V* in Japan. Abbott also expands its emerging markets footprint by acquiring Solvay Pharmaceuticals and Piramal Healthcare Solutions, making it number one in India.

Rankings

Abbott is ranked among the top companies in the world for financial strength and workplace excellence by leading national publications and organizations, including:

- Barron's** Ranked 28th on *Barron's* "World's Most Respected Companies" list.
- Named Miles White to its list of "World's Best CEOs" for the 3rd consecutive year.
- DiversityInc** Named one of the "Top Companies for Diversity" for the 8th consecutive year.
- DJSI** Included in the Dow Jones Sustainability Investor (DJSI) for the 6th consecutive year.
- Forbes** Ranked 105th on the *Forbes Global 2000* list (ranked by 2009 sales, profits, assets and market value).
- Fortune** Ranked 4th among the "Most Admired Companies" in the pharmaceutical sector.
- Ranked 75th on the *Fortune 500* list of the largest U.S.-based corporations (ranked by 2009 revenue).
- NAFE** Top 10 Companies for Women Leaders by the National Association for Female Executives (NAFE).
- Science** Top BioPharma employer.
- The Scientist** Ranked 4th on the "Best Places to Work in Industry" list.
- Scrip** Named Pharma Company and Management Team of the Year.
- Working Mother** Named one of the best companies for working mothers for the 10th consecutive year.

Our commitment

We view our commitment to global citizenship as another opportunity to improve lives around the world.



Nearly 80 Abbott volunteers inspired more than 130 students and families during science workshops in Shanghai.

Abbott aligns our strategies for business growth and profitability with our citizenship and sustainability priorities. We work for the benefit of patients, consumers, shareholders and health care systems. We are redefining responsibility by empowering our people around the world to help develop innovative, sustainable solutions.

Our efforts have earned Abbott inclusion in the Dow Jones Sustainability Index — the leading benchmark for citizenship performance — for six consecutive years, and we continuously challenge ourselves to do more.

Abbott has established four strategic priorities to align citizenship activities with business operations: innovating for the future, enhancing access to care, protecting patients and consumers, and safeguarding the environment. These four priorities continue to help guide our day-to-day business decisions.

In 2010, we made significant progress toward redefining responsibility across our diverse mix of businesses. For instance, more than one million students and their families in five countries participated in our science education programs. Led by Abbott volunteers, these activities are designed to inspire the next generation of scientists.

We partnered with the Drugs for Neglected Diseases initiative (DNDi) to identify thousands of compounds in Abbott's research library that may help address tropical diseases that disproportionately impact the developing world. We also are working with leading nonprofit organizations on population-based approaches to limit the spread of these ailments.

We announced an aggressive, five-year plan to decrease our environmental footprint. Our aim is to reduce carbon dioxide emissions by 15 percent and water use by 50 percent by the year 2015 from 2005 levels. We will meet these commitments through a variety of innovations, including cogeneration (reuse of energy), alternative energy installations and process improvements.

We are partnering with governments, health care professional organizations and leaders to drive our citizenship priorities at the country level. This year, we conducted training workshops and initiated public-private partnerships in numerous markets, including Brazil, China, India, Ireland, Italy, Singapore, the United Kingdom, the United States and Vietnam.

For a copy of our Global Citizenship Report, please visit abbott.com/citizenship.

Five-Year Financial Summary

(dollars in millions, except per share data)

Year Ended December 31	2010	2009	2008	2007	2006
Summary of Operations:					
Net sales	\$35,166.7	30,764.7	29,527.6	25,914.2	22,476.3
Cost of products sold	\$14,665.2	13,209.3	12,612.0	11,422.0	9,815.1
Research and development (a)	\$ 3,724.4	2,743.7	2,688.1	2,505.6	2,255.3
Selling, general and administrative	\$10,376.3	8,405.9	8,435.6	7,408.0	6,349.7
Operating earnings	\$ 6,087.6	6,235.7	5,693.8	4,578.5	2,042.2
Interest expense	\$ 553.1	519.7	528.5	593.1	416.2
Interest income	\$ (105.5)	(137.8)	(201.2)	(136.8)	(123.8)
Other (income), net	\$ (62.0)	(1,375.5)	(489.7)	(347.5)	(526.5)
Earnings from continuing operations before taxes	\$ 5,712.8	7,193.8	5,856.3	4,469.6	2,276.4
Taxes on earnings from continuing operations	\$ 1,086.7	1,447.9	1,122.1	863.3	559.6
Earnings from continuing operations	\$ 4,626.2	5,745.8	4,734.2	3,606.3	1,716.8
Basic earnings per share from continuing operations	\$ 2.98	3.71	3.06	2.34	1.12
Diluted earnings per share from continuing operations	\$ 2.96	3.69	3.03	2.31	1.12
Financial Position:					
Working capital	\$ 5,055.1	10,264.4	5,106.8	4,939.5	(669.3)
Long-term investments	\$ 302.0	1,132.9	1,073.7	1,125.3	1,229.9
Net property and equipment	\$ 7,971.0	7,619.5	7,219.2	7,518.1	6,946.4
Total assets	\$59,462.3	52,416.6	42,419.2	39,713.9	36,178.2
Long-term debt	\$12,523.5	11,266.3	8,713.3	9,487.8	7,009.7
Shareholders' investment	\$22,476.5	22,898.7	17,518.7	17,823.9	14,054.2
Return on shareholders' investment from continuing operations	% 20.4	28.4	26.9	22.7	12.1
Book value per share	\$ 14.53	14.76	11.26	11.47	9.14
Other Statistics:					
Gross profit margin	% 58.3	57.1	57.3	55.9	56.3
Research and development to net sales	% 10.6	8.9	9.1	9.7	10.0
Net cash from operating activities of continuing operations	\$ 8,736.0	7,275.2	6,994.6	5,183.8	5,262.1
Capital expenditures	\$ 1,015.1	1,089.0	1,287.7	1,656.2	1,337.8
Cash dividends declared per common share	\$ 1.76	1.60	1.44	1.30	1.18
Common shares outstanding (in thousands)	1,546,984	1,551,168	1,552,433	1,549,910	1,537,243
Number of common shareholders	64,413	67,461	69,733	73,176	77,727
Number of employees	91,440	72,868	68,838	68,697	66,663
Sales per employee (in dollars)	\$ 384,588	422,198	428,943	377,225	337,163
Market price per share – high	\$ 56.79	57.39	61.09	59.50	49.87
Market price per share – low	\$ 44.59	41.27	45.75	48.75	39.18
Market price per share – close	\$ 47.91	53.99	53.37	56.15	48.71

(a) In 2010, 2009 and 2006 Abbott also recorded pretax charges of \$313, \$170 and \$2,014, respectively, for acquired in-process research and development.

Plant Locations

Abbott's corporate offices are located at 100 Abbott Park Road, Abbott Park, Illinois 60064-6400. The locations of Abbott's principal plants, as of December 31, 2010, are listed below.

Abbott Park, Illinois	Ludwigshafen, Germany
Alameda, California*	Milpitas, California*
Alcobendas, Spain	Murrieta, California
Altavista, Virginia	Neustadt, Germany
Anasco, Puerto Rico	North Chicago, Illinois
Barceloneta, Puerto Rico	Olst, Netherlands
Brockville, Canada	Ottawa, Ontario, Canada*
Buenos Aires, Argentina	Redwood City, California*
Campoverde di Aprilia, Italy	Rio de Janeiro, Brazil
Casa Grande, Arizona	Santa Clara, California
Chatillon, France	Singapore
Cionmel, Ireland	Sligo, Ireland
Columbus, Ohio	Sturgis, Michigan
Cootehill, Ireland	Temecula, California
Dartford, England*	Tlalpan, Mexico
Des Plaines, Illinois	Uppsala, Sweden
Fairfield, California*	Weesp, Netherlands
Granada, Spain	Wiesbaden, Delkenheim, Germany
Irving, Texas	Witney, Oxon, England
Jayuya, Puerto Rico	Worcester, Massachusetts
Kanata, Ontario, Canada	Zwolle, the Netherlands
Karachi, Pakistan	
Katsuyama, Japan	*Leased property
Longford, Ireland	

Directors

Robert J. Alpern, M.D.
*Dean, Yale School of Medicine
New Haven, Conn.*

Roxanne S. Austin
*Former President and
Chief Executive Officer,
Move Networks Inc.
American Fork, Utah*

W. James Farrell
*Retired Chairman and
Chief Executive Officer,
Illinois Tool Works Inc.
Glenview, Ill.*

H. Laurance Fuller
*Retired Co-Chairman
of the Board,
BP Amoco p.l.c.
London, United Kingdom*

Edward M. Liddy
*Partner,
Clayton, Dubilier & Rice LLC
New York, NY*

Phebe N. Novakovic
*Executive Vice President,
Marine Systems,
General Dynamics Corporation
Falls Church, Va.*

William A. Osborn
*Retired Chairman and
Chief Executive Officer,
Northern Trust Corporation
and The Northern Trust Co.
Chicago, Ill.*

Samuel C. Scott III
*Retired Chairman, President
and Chief Executive Officer,
Corn Products International Inc.
Westchester, Ill.*

Glenn F. Tilton
*Non-Executive Chairman
of the Board,
United Continental Holdings Inc.
Chicago, Ill.*

Miles D. White
*Chairman of the Board
and Chief Executive Officer,
Abbott*

Senior Management

Miles D. White*
*Chairman of the Board
and Chief Executive Officer*

Thomas C. Freyman*
*Executive Vice President,
Finance and Chief
Financial Officer*

Richard W. Ashley*
*Executive Vice President,
Corporate Development*

John M. Capek, Ph.D.*
*Executive Vice President,
Medical Devices*

Richard A. Gonzalez*
*Executive Vice President,
Pharmaceutical
Products Group*

John C. Landgraf*
*Executive Vice President,
Nutritional Products*

Edward L. Michael*
*Executive Vice President,
Diagnostics Products*

Laura J. Schumacher*
*Executive Vice President,
General Counsel
and Secretary*

Carlos Alban*
*Senior Vice President,
Proprietary Pharmaceutical
Products, Global
Commercial Operations*

Brian J. Blaser*
*Senior Vice President,
Diagnostics*

David Forrest*
*Senior Vice President,
International Nutrition*

Stephen R. Fussell*
*Senior Vice President,
Human Resources*

Robert B. Hance*
*Senior Vice President,
Vascular*

John M. Leonard, M.D.
*Senior Vice President,
Pharmaceuticals,
Research and Development*

Heather L. Mason*
*Senior Vice President,
Diabetes Care*

James V. Mazzo*
*Senior Vice President,
Abbott Medical Optics*

Mary T. Szela*
*Senior Vice President,
Global Strategic
Marketing and Services,
Pharmaceutical
Products Group*

Michael J. Warmuth*
*Senior Vice President,
Established Products*

J. Scott White*
*Senior Vice President,
U.S. Nutrition*

Corporate Vice Presidents

Greg E. Arnsdorff
*Vice President,
Point of Care Diagnostics*

Michael G. Beatrice, Ph.D.
*Vice President,
Corporate Regulatory
and Quality Science*

William J. Chase
*Vice President, Licensing
and Acquisitions*

Jaime Contreras
*Vice President,
International Diagnostics*

Thomas J. Dee
*Vice President, International
Finance Operations*

Charles D. Foltz
*Vice President,
Vascular Products
Operations*

Robert B. Ford
*Vice President,
Diabetes Care,
Commercial Operations*

Robert E. Funck
*Vice President, Chief Ethics
and Compliance Officer*

John F. Ginasool
*Vice President,
Nutrition Supply Chain*

Honey Lynn Goldberg
*Vice President,
Associate General Counsel,
Corporate Transactions*

Thomas A. Hurwich
*Vice President,
Internal Audit*

Cecilia L. Kimberlin, Ph.D.
*Vice President, Quality,
Medical Products*

Elaine R. Leavenworth
*Vice President,
Government Affairs*

Steven J. Lichter
*Vice President,
Established Products,
Operations*

Greg W. Linder*
Vice President, Controller

Santiago Luque
*Vice President,
Pharmaceuticals,
Latin America*

Brendan McAtamney
*Vice President, Established
Products, Commercial*

Corlis D. Murray
*Vice President,
Corporate Engineering
Services*

D. Stafford O'Kelly
*Vice President,
Molecular Diagnostics*

Ramachandran
Rajamanickam
*Vice President, Nutrition,
Pacific, Asia and Africa*

Pascale Richetta
*Vice President,
Pharmaceuticals, Western
Europe and Canada*

Ronald O. Robison
*Vice President,
Regulatory Affairs,
Pharmaceutical
Products Group*

Azita Saleki-Gerhardt, Ph.D.
*Vice President,
Pharmaceuticals,
Manufacturing and Supply*

John R. Schilling, M.D.
*Vice President,
Sales and Marketing,
Pharmaceutical Products*

AJ J. Shultz
Vice President, Taxes

Preston T. Simons
*Vice President,
Information Technology*

Jeffrey R. Stewart
*Vice President,
Proprietary
Pharmaceuticals,
United States*

James P. Sullivan, Ph.D.
*Vice President,
Pharmaceuticals Discovery*

Eugene Sun, M.D.
*Vice President,
Pharmaceuticals
Clinical Development*

John B. Thomas
*Vice President,
Investor Relations and
Public Affairs*

Glenn S. Warner
*Vice President,
Strategic Initiatives,
Pharmaceutical
Products Group*

Susan M. Widner
*Vice President,
Corporate Marketing*

Gary M. Winer
*Vice President,
Pharmaceuticals, Japan*

Valentine Yien
Vice President, Treasurer

*Denotes executive officer

Published by Abbott Investor Relations and Public Affairs
Investor Newsline: (847) 937-7300

The ticker symbol for Abbott's common stock is ABT. The principal market for Abbott's common shares is the New York Stock Exchange. Shares are also listed on the Chicago Stock Exchange and traded on various regional and electronic exchanges. Outside the United States, Abbott's shares are listed on the London Stock Exchange and the Swiss Stock Exchange.

On the cover: *Thyronorm* – Dr. Madhuri Kulkarni, Mumbai, India

Dr. Madhuri Kulkarni is one of the many patients who take *Thyronorm*, elsewhere known as *Synthroid*, to treat hypothyroidism (under-active thyroid). As a patient advocate, she is educating men and women in India about the symptoms of thyroid disease.

Abbott trademarks and products in-licensed by Abbott are shown in italics in the text of this Fact Book.

Herceptin is not a trademark of Abbott Laboratories.

Not all products listed are approved in all countries.

©2011, Abbott Laboratories 25M/4/11



The Abbott 2011 Fact Book was printed with the use of renewable wind power resulting in nearly zero carbon emissions, keeping 747.85 pounds of CO₂ from the atmosphere. This amount of wind-generated electricity is equivalent to 648.85 miles not driven in an automobile or 50.87 trees planted.

Abbott
100 Abbott Park Road
Abbott Park, IL 60064-6400 U.S.A.
(847) 937-6100 www.abbott.com

 **Abbott**
A Promise for Life